ABATACEPT
Abatacept is a selective immunomodulator that inhibits T‑cell activation by binding to CD80/86 on antigen-presenting cells, blocking the CD28 costimulatory signal. It is indicated for rheumatoid arthritis and other autoimmune diseases. Benefits include sustained symptom improvement and favorable tolerability. Side effects include headache, mild infections, and nausea, with rare increased risk of serious infections during long-term therapy.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP Manufacturers
Let us handle your sourcing / supply activities. For years we have sourced specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
We are committed to supplying high-quality GMP products with logistics accoring to GDP regulations
Product Description
Mechanism of action
Abatacept is a fusion protein consisting of the extracellular domain of CTLA‑4 linked to an IgG1 Fc fragment. It selectively modulates T‑cell activation by binding to CD80/CD86 on antigen‑presenting cells, thereby blocking their interaction with CD28 on T lymphocytes. This prevents the necessary co‑stimulatory signal for full T‑cell activation and reduces downstream inflammatory responses.
Benefits and advantages
By targeting a key step in adaptive immune activation, abatacept provides effective disease‑modifying activity in rheumatoid arthritis and other autoimmune indications when formulated as an injectable biologic. Its selective mechanism offers an alternative to broad immunosuppressants and can be combined with conventional disease‑modifying antirheumatic drugs in appropriate patients.
Side effects and risks
As an immunomodulator, abatacept increases susceptibility to infections, including serious and opportunistic pathogens. Other adverse effects may include infusion‑related reactions, headache, nausea and possible exacerbation of chronic obstructive pulmonary disease. Long‑term immunosuppression can be associated with an elevated risk of malignancy. Manufacturing, handling and clinical use must therefore follow stringent regulatory requirements.
Datasheet
| Molecular Formula | C3498H5458N922O1090S32 |
|---|---|
| Molecular Weight | 92300 g/mol |
| CAS Number | 332348-12-6 |
| Storage Condition | Store refrigerated at 28 °C. Do not freeze. |
| Solubility | Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance. |
| Purity | Purity information is available upon request (COA). |
| Synonym | Abatacept; Orencia; CTLA4-Ig; BMS-188667; 332348-12-6 |
| IUPAC/Chemical Name | Fusion protein of the extracellular domain of human CTLA-4 linked to the modified Fc (hinge, CH2, CH3 domains) of human IgG1 (CTLA4-Ig) |
| References |
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
